MX365302B - Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno. - Google Patents

Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.

Info

Publication number
MX365302B
MX365302B MX2014012694A MX2014012694A MX365302B MX 365302 B MX365302 B MX 365302B MX 2014012694 A MX2014012694 A MX 2014012694A MX 2014012694 A MX2014012694 A MX 2014012694A MX 365302 B MX365302 B MX 365302B
Authority
MX
Mexico
Prior art keywords
methods
phenylacetic acid
paa
therapeutic monitoring
acid prodrugs
Prior art date
Application number
MX2014012694A
Other languages
English (en)
Other versions
MX2014012694A (es
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX365302(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of MX2014012694A publication Critical patent/MX2014012694A/es
Publication of MX365302B publication Critical patent/MX365302B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención proporciona métodos para ajustar la dosificación de profármaco de PAAs (por ejemplo, HPN-100, PBA) con base en la medición de PAA y PAGN en plasma y calcular la relación de PAA:PAGN para así determinar si la conversión de PAA a PAGN es saturada.
MX2014012694A 2012-04-20 2012-09-11 Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno. MX365302B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
PCT/US2012/054673 WO2013158145A1 (en) 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs

Publications (2)

Publication Number Publication Date
MX2014012694A MX2014012694A (es) 2015-06-03
MX365302B true MX365302B (es) 2019-05-29

Family

ID=49380684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012694A MX365302B (es) 2012-04-20 2012-09-11 Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.

Country Status (25)

Country Link
US (4) US9561197B2 (es)
EP (2) EP3222275B1 (es)
JP (3) JP6234436B2 (es)
KR (2) KR102264579B1 (es)
CN (3) CN111991383A (es)
AU (3) AU2012377389A1 (es)
BR (1) BR112014026138A2 (es)
CL (2) CL2014002807A1 (es)
CY (1) CY1118838T1 (es)
DK (1) DK2846791T3 (es)
EC (1) ECSP14024561A (es)
ES (2) ES2623470T3 (es)
HK (2) HK1208380A1 (es)
HR (1) HRP20170651T1 (es)
HU (1) HUE032726T2 (es)
IL (2) IL235127A (es)
LT (1) LT2846791T (es)
MX (1) MX365302B (es)
PL (1) PL2846791T3 (es)
PT (1) PT2846791T (es)
RS (1) RS55870B1 (es)
SG (2) SG10201608749UA (es)
SI (1) SI2846791T1 (es)
WO (1) WO2013158145A1 (es)
ZA (1) ZA201407597B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
EP3222275B1 (en) 2012-04-20 2020-06-24 Immedica Pharma AB Methods of therapeutic monitoring of phenylacetic acid prodrugs
LT2922576T (lt) * 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
ES2746999T3 (es) 2013-10-14 2020-03-09 Immedica Pharma Ab Métodos de tratamiento de trastornos del ciclo de la urea
US20170087113A1 (en) * 2014-06-04 2017-03-30 Horizon Therapeutics, Llc Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) * 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0858441B1 (en) 1995-02-07 2001-05-09 Brusilow Enterprises, LLC Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
EP2319581B1 (en) 2004-11-26 2015-02-25 UCL Business PLC Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en) 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
LT2330892T (lt) * 2008-08-29 2016-11-25 Horizon Therapeutics, Inc. Gydymo būdai panaudojant vaistus - amoniako gaudykles
CA2735234A1 (en) * 2008-08-29 2010-03-04 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
EP3222275B1 (en) * 2012-04-20 2020-06-24 Immedica Pharma AB Methods of therapeutic monitoring of phenylacetic acid prodrugs
LT2922576T (lt) 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai

Also Published As

Publication number Publication date
US20170266143A1 (en) 2017-09-21
AU2012377389A1 (en) 2014-10-30
CY1118838T1 (el) 2018-01-10
US9561197B2 (en) 2017-02-07
ECSP14024561A (es) 2015-09-30
RS55870B1 (sr) 2017-08-31
EP2846791A4 (en) 2015-08-19
HK1208380A1 (en) 2016-03-04
IL235127A (en) 2017-12-31
AU2018200163B2 (en) 2018-12-20
EP2846791B1 (en) 2017-02-08
IL255918B (en) 2019-06-30
HUE032726T2 (en) 2017-10-30
EP2846791A1 (en) 2015-03-18
CL2017001375A1 (es) 2018-01-05
EP3222275B1 (en) 2020-06-24
JP6234436B2 (ja) 2017-11-22
HRP20170651T1 (hr) 2017-06-30
DK2846791T3 (en) 2017-03-27
HK1243959A1 (zh) 2018-07-27
BR112014026138A2 (pt) 2017-06-27
ZA201407597B (en) 2017-05-31
IL255918A (en) 2018-01-31
CL2014002807A1 (es) 2015-02-27
PL2846791T3 (pl) 2017-07-31
ES2623470T3 (es) 2017-07-11
JP2015514757A (ja) 2015-05-21
PT2846791T (pt) 2017-05-25
WO2013158145A1 (en) 2013-10-24
KR20190116552A (ko) 2019-10-14
JP2018039830A (ja) 2018-03-15
WO2013158145A9 (en) 2014-05-01
AU2019201811B2 (en) 2020-07-09
US20180263938A1 (en) 2018-09-20
CN111991383A (zh) 2020-11-27
US20180015058A1 (en) 2018-01-18
US20130281530A1 (en) 2013-10-24
AU2018200163A1 (en) 2018-02-01
MX2014012694A (es) 2015-06-03
SI2846791T1 (sl) 2017-06-30
KR102264579B1 (ko) 2021-06-11
EP3222275A1 (en) 2017-09-27
KR20150013170A (ko) 2015-02-04
LT2846791T (lt) 2017-04-10
JP6637941B2 (ja) 2020-01-29
SG10201608749UA (en) 2016-12-29
CN113995743A (zh) 2022-02-01
ES2807951T3 (es) 2021-02-24
JP2019219413A (ja) 2019-12-26
CN104540507A (zh) 2015-04-22
AU2019201811A1 (en) 2019-04-04
SG11201406745VA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
MX365302B (es) Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.
MX2017008380A (es) Compuestos, composiciones y metodos para incrementar la actividad del regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
GEP201706768B (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
HUE049168T2 (hu) L-aminosav elõállítására képes mikroorganizmus és eljárás L-aminosav elõállítására annak alkalmazásával
HK1197230A1 (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
PH12015500590A1 (en) Apixaban liquid formulations
MX340816B (es) Compuestos que inhiben el glioblastoma y su uso.
IN2014MN02114A (es)
MY185501A (en) Electrical energy calculation system
IN2014KN02745A (es)
IN2014CN04521A (es)
MX2015002693A (es) Permeabilidad de celda de flujo y sistema de conductancia hidraulica.
MX2015002694A (es) Permeabilidad de la celda de flujo y sistema de conductancia hidraulica.
GB2509663A (en) Treatment of adrenal insufficiency
WO2015023631A3 (en) Fatty acid analogs and their use
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.
MX2015002691A (es) Celda de flujo de permeabilidad y sistema de conductancia hidraulica.
MX2015002692A (es) Permeabilidad de celda de flujo y sistema de conductancia hidraulica.
IN2013KO01452A (es)
UA52523U (ru) Микропроцессорный измеритель поляризационного сопротивления
ZA201308320B (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
UA67342U (ru) Способ оценки жизненной емкости легких у здоровых людей
UA64913U (ru) Применение маркера опухолей 99МТс-технефора в качестве указателя участка воспаления при диагностировании остеомиелита нижней челюсти

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: HORIZON THERAPEUTICS, LLC

HC Change of company name or juridical status

Owner name: HORIZON THERAPEUTICS, LLC

FG Grant or registration